Financial Contrast: Mainz Biomed (NASDAQ:MYNZ) and StandardAero (NYSE:SARO)

Mainz Biomed (NASDAQ:MYNZ) and StandardAero (NYSE:SARO) are both industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Earnings & Valuation

This table compares Mainz Biomed and StandardAero”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659,935.00	15.38	-$21.65 million	($65.60)	-0.02
StandardAero	$6.32 billion	1.06	$277.42 million	$0.97	20.79

StandardAero has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than StandardAero, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Mainz Biomed and StandardAero, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1	1	0	0	1.50
StandardAero	0	6	7	2	2.73

StandardAero has a consensus target price of $34.00, suggesting a potential upside of 68.58%. Given StandardAero’s stronger consensus rating and higher possible upside, analysts clearly believe StandardAero is more favorable than Mainz Biomed.

Volatility and Risk

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, StandardAero has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Mainz Biomed and StandardAero’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
StandardAero	5.12%	14.52%	5.80%

Summary

StandardAero beats Mainz Biomed on 12 of the 13 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About StandardAero

StandardAero, Inc. provides aerospace engine aftermarket services for fixed and rotary wing aircraft in the United States, Canada, the United Kingdom, Rest of Europe, Asia, and internationally. It operates in two segments, Engine Services and Component Repair Services. The Engine Services segment provides a suite of aftermarket services, including maintenance, repair and overhaul, on-wing and field service support, asset management, and engineering and related solutions to customers in the commercial aerospace, military and helicopter, and business aviation end markets. The Component Repair Services segment offers engine component and accessory repairs to the commercial aerospace, military and helicopter, land and marine, and oil and gas end markets. The company was founded in 1911 and is headquartered in Scottsdale, Arizona.